Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Dyax completes BLA for hereditary angioedema drug
Dyax has requested priority review, which, if granted, would set a target date of six months from receipt of the completed submission for the FDA to take action
Dyax has requested priority review, which, if granted, would set a target date of six months from receipt of the completed submission for the FDA to take action
Oramed’s Phase IIa trial is focused on assessing the safety and efficacy of its oral insulin capsule on nine Type 1 diabetes patients. The start of this clinical
In accordance with the new agreement scientists from ChemBridge and AstraZeneca will work together to design and develop a new generation of highly advanced, research intensive small molecule
To begin leveraging a key part of the system right away, M D Anderson deployed Provantis Pathology using Instem’s remote hosted online model, allowing pathologists to access the
These applications include ultra-deep amplicon sequencing for detection of low-frequency mutations in disease associated genes, and the comprehensive identification and quantification of common and rare variants within a
In addition, the company has completed the relocation of its headquarters to 19204 North Creek Parkway, Suite 100 Bothell, Washington. The facility includes approximately 20,500sqft of R&D facilities
Most recently, Mr Pope served as worldwide president of Cordis, a multibillion dollar franchise within Johnson and Johnson’s medical device sector. Mr Pope is a graduate of the
As part of the agreement, the companies will utilize GE’s global research center and its advanced work in clinical parameters and monitoring algorithms to drive innovation in the
The trial was designed as a multi-centre, double-blind comparative study. Patients suffering from complicated skin and skin structure infections (cSSSI) received intravenous (IV) vancomycin for the first two
Each unit was priced at $7 and consisted of one share of PolyMedix convertible preferred stock and a five year warrant initially exercisable for one share of PolyMedix